Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Managed Markets Insight & Technology (MMIT)